Element Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Element Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-35,720	Closed	-$57K	–	1028
2018 Q4	$57K	Sell	35,720 -51,452	-59%	-$145K	﹤0.01%	637
2018 Q3	$321K	Buy	+87,172	New	+$260K	0.01%	574
2018 Q2	–	Sell	-43,821	Closed	-$163K	–	1090
2018 Q1	$163K	Buy	+43,821	New	+$143K	﹤0.01%	719

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Element Capital Management's ACHN Position: Q1 2019 in Review

Element Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2019, closing a stake of 35,720 shares — an estimated $57K sold.

Element Capital Management first reported a position in ACHN in Q1 2018 and held it in 3 quarters. The position peaked at $321K in Q3 2018. 110 funds tracked by Wall St. Rank hold ACHN as of Q1 2019.

Element Capital Management reported no remaining Achillion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Element Capital Management sold 35,720 Achillion Pharmaceuticals shares in Q1 2019, an estimated $57K.
Element Capital Management first reported a position in Achillion Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Element Capital Management's Achillion Pharmaceuticals position peaked at $321K in Q3 2018.
110 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2019.

Based on Element Capital Management's 13F filing for Q1 2019, filed 13 May 2019.